BANGALORE, India — SciClone Pharmaceuticals Inc. said its adjuvant, Zadaxin, in combination with Novartis' H1N1 vaccine increased immune response, Reuters reported Jan. 12.
An adjuvant is an ingredient that boosts the immune-system response, which means that less of the active ingredient is needed in each dose.
Zadaxin given with the MF59 adjuvanted H1N1 influenza monovalent vaccine Focetria led to a significant increase in the percentage of subjects who seroconverted at 21 days after vaccination, compared to those who received the vaccine alone, SciClone said.
SciClone, and its partner Sigma-Tau S.p.A said 89 percent of patients in the low-dose Zadaxin arm achieved seroconversion — a significant increase in specific antibody — as did 88 percent of patients in the high-dose arm, compared to 56 percent in the vaccine-only arm.
Seroconversion is defined as a four fold or greater change in titers from baseline.
The randomized, three-arm open label study has a planned duration of six months and hence is still ongoing.